- Report
- October 2024
- 188 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- March 2025
- 195 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- April 2025
- 381 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- August 2022
- 118 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- March 2021
- 102 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- January 2022
- 70 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- January 2022
- 60 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- March 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,826GBP
- Report
- August 2022
- 113 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- November 2021
- 193 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- November 2021
- 82 Pages
Asia Pacific
From €1365EUR$1,500USD£1,160GBP
- Report
- November 2021
- 71 Pages
North America
From €1365EUR$1,500USD£1,160GBP
- Report
- November 2021
- 82 Pages
Africa, Middle East
From €1365EUR$1,500USD£1,160GBP

Filgrastim is a type of oncology drug used to treat neutropenia, a condition in which the body does not produce enough white blood cells. It is a recombinant form of human granulocyte colony-stimulating factor (G-CSF), a naturally occurring hormone that stimulates the production of white blood cells. Filgrastim is used to reduce the risk of infection in patients undergoing chemotherapy or bone marrow transplantation. It is also used to treat severe chronic neutropenia, a rare condition in which the body does not produce enough white blood cells.
Filgrastim is available in both injectable and subcutaneous forms. The injectable form is administered intravenously, while the subcutaneous form is injected under the skin. Filgrastim is typically administered once a day for five to seven days.
Filgrastim is a widely used oncology drug, with many companies producing and marketing it. Some of these companies include Amgen, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more